Some U.S. biotech companies are debating on relocating their early-stage trials of new medicines outside the U.S. due to worries that layoffs and policy changes at the U.S. Food and Drug Administration by the Trump administration may lead to delays in regulatory reviews, Maggic Fick of Reuters reports, citing executives, investors, and consultants. Publicly traded companies in the space include AstraZeneca (AZN), Bristol Myers (BMY), Eli Lilly (LLY), GSK (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- Trump’s drug-price crackdown may lead to minor concessions, WSJ reports
- JPMorgan sees ‘most favored nation’ drug order facing ‘significant push back’
- Pharma Stocks Rally despite Trump’s Plan to Cut Drug Prices
- White House publishes Trump executive order aimed at lowering drug prices
- AstraZeneca’s Trixeo Aerosphere approved for use in UK with propellant